![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
J Balzarini, H Pelemans, S Aquaro, CF Perno, M Witvrouw, D Schols, E De Clercq and A Karlsson
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium. jan.balzarini@rega.kuleuven.ac.be
The novel human immunodeficiency virus type 1-specific thiocarboxanilide derivatives that contain either a substituted furanyl (UC-781) or thienyl (UC-82) ring linked to the thiocarboxy group and a pentenyloxyether chain linked to the 4-chlorophenyl ring in meta position show highly favorable antiviral properties. Compounds UC-781 and UC-82 discovered by scientists at Uniroyal Chemical Ltd. proved to be > or = 5-10-fold more inhibitory to wild-type human immunodeficiency virus type 1 strains (EC50 approximately 0.002 microgram/ml) than the thiocarboxanilide oxime ether UC-10 and other non-nucleoside reverse transcriptase inhibitors such as nevirapine, bis(heteroaryl)piperazine, and tetrahydroimidazo[4,5,l-jk][1,4]-benzodiazepin-2(1H)-one. In addition, the compounds were able to knock out virus replication in cell culture at concentrations that were 20-50-fold lower than those of nevirapine or bis(heteroaryl)piperazine. They were also highly efficient (EC50 < or = 0.02 microgram/ml) in suppressing the replication of mutant virus strains that contained mutations in their reverse transcriptase that conferred resistance to other non-nucleoside reverse transcriptase inhibitors (i.e., Tyr181 to Cys, Lys103 to Asn, Val106 to Ala, and Leu100 to Ile). The compounds selected for virus mutants that were only marginally resistant to the thiocarboxanilides ( < 10-20-fold). The antiviral activity of the compounds was only slightly affected by the presence of high concentrations of human serum, and the compounds were shown to be highly stable in the presence of human serum for at least 24 hr at room temperature.
This article has been cited by other articles:
|
|
 |
|
  P. M. M. Mesquita, S. S. Wilson, P. Manlow, L. Fischetti, M. J. Keller, B. C. Herold, and R. J. Shattock Candidate Microbicide PPCM Blocks Human Immunodeficiency Virus Type 1 Infection in Cell and Tissue Cultures and Prevents Genital Herpes in a Murine Model J. Virol., July 1, 2008; 82(13): 6576 - 6584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Basavapathruni and K. S. Anderson Reverse transcription of the HIV-1 pandemic FASEB J, December 1, 2007; 21(14): 3795 - 3808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Madan, P. M. M. Mesquita, N. Cheshenko, B. Jing, V. Shende, E. Guzman, T. Heald, M. J. Keller, S. L. Regen, R. J. Shattock, et al. Molecular Umbrellas: a Novel Class of Candidate Topical Microbicides To Prevent Human Immunodeficiency Virus and Herpes Simplex Virus Infections J. Virol., July 15, 2007; 81(14): 7636 - 7646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. J. D'Cruz and F. M. Uckun Dawn of non-nucleoside inhibitor-based anti-HIV microbicides J. Antimicrob. Chemother., March 1, 2006; 57(3): 411 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Basavapathruni, C. M. Bailey, and K. S. Anderson Defining a Molecular Mechanism of Synergy between Nucleoside and Nonnucleoside AIDS Drugs J. Biol. Chem., February 20, 2004; 279(8): 6221 - 6224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Borkow, D. Arion, M. A. Wainberg, and M. A. Parniak The Thiocarboxanilide Nonnucleoside Inhibitor UC781 Restores Antiviral Activity of 3'-Azido-3'-Deoxythymidine (AZT) against AZT-Resistant Human Immunodeficiency Virus Type 1 Antimicrob. Agents Chemother., February 1, 1999; 43(2): 259 - 263. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. M. Esnouf, J. Ren, A. L. Hopkins, C. K. Ross, E. Y. Jones, D. K. Stammers, and D. I. Stuart Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor PNAS, April 15, 1997; 94(8): 3984 - 3989. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
